Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia

Lynn R Webster, Marvin Tark, Richard Rauck, Jeffrey K Tobias, Geertrui F Vanhove, Lynn R Webster, Marvin Tark, Richard Rauck, Jeffrey K Tobias, Geertrui F Vanhove

Abstract

Background: Postherpetic neuralgia (PHN) is a painful and difficult to treat complication of acute herpes zoster. Current treatment options provide only partial relief and are often limited by poor tolerability. We evaluated the safety and efficacy of a single 60-minute application of NGX-4010, an 8% capsaicin patch, in patients with PHN.

Methods: This multicenter, double-blind, controlled study randomized 155 patients 2:1 to receive either NGX-4010 or a 0.04% capsaicin control patch. Patients were at least 18 years old with PHN for at least 3 months, and an average Numeric Pain Rating Scale (NPRS) score of 3 to 9. The primary efficacy endpoint was the percentage change in NPRS score from baseline to weeks 2-8.

Results: The mean percent reduction in "average pain for the past 24 hours" NPRS scores from baseline to weeks 2-8 was greater in the NGX-4010 group (36.5%) compared with control (29.9%) although the difference was not significant (p = 0.296). PGIC analysis demonstrated that more NGX-4010 recipients considered themselves improved (much, or very much) compared with control at weeks 8 and 12, but the differences did not reach statistical significance. Post hoc analyses of patients with PHN for at least 6 months showed significantly greater reductions in "average pain for the past 24 hours" NPRS scores from baseline to weeks 2-8 in NGX-4010 patients compared to controls (37.6% versus 23.4%; p = 0.0291). PGIC analysis in this subgroup demonstrated that significantly more NGX-4010 recipients considered themselves much or very much improved compared with control at week 12 (40% versus 20%; p = 0.0403;).

Conclusions: Although treatment appeared to be safe and well tolerated, a single 60-minute application of NGX-4010 failed to show efficacy in this study which included patients with PHN for less than 6 months. Large reductions in pain observed among control patients with pain for less than 6 months may have been due to spontaneous resolution of PHN, may have confounded the results of the prespecified analyses, and should be taken into account when designing PHN studies.

Trial registration: NCT00068081.

Figures

Figure 1
Figure 1
Study randomization and disposition.
Figure 2
Figure 2
Percent change from baseline in "average pain for the past 24 Hours" NPRS scores by week. Values shown are mean and standard error of the mean (SEM). NGX-4010 showed greater improvement in pain scores at weeks 1 through 8 but the differences between the two groups diminished over time largely due to continued improvement in the control group.
Figure 3
Figure 3
Change in "Pain Now" NPRS scores from pre-anesthetic time point during the treatment procedure. Values shown are mean and SEM. "Pain Now" NPRS scores decreased following topical anesthetic and increased following patch application in both treatment groups. Patients receiving NGX-4010 reported a mean maximum increase of 1.9 from the pre-anesthetic time point. NPRS scores did not increase above pre-procedure levels in those receiving control. NPRS scores in the NGX-4010 group decreased to below pre-procedure levels at 85 minutes after patch removal.

References

    1. Rowbotham MC, Petersen KL. Zoster-associated pain and neural dysfunction. Pain. 2001;93:1–5. doi: 10.1016/S0304-3959(01)00328-1.
    1. Johnson RW, Dworkin RH. Treatment of herpes zoster and postherpetic neuralgia. BMJ. 2003;326:748–750. doi: 10.1136/bmj.326.7392.748.
    1. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain. 2002;18:350–354. doi: 10.1097/00002508-200211000-00002.
    1. Watson CP. A new treatment for postherpetic neuralgia. N Engl J Med. 2000;343:1563–1565. doi: 10.1056/NEJM200011233432110.
    1. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305. doi: 10.1016/j.pain.2005.08.013.
    1. Backonja M, Irving G, Argoff C. Rational Multidrug Therapy in the Treatment of Neuropathic Pain. Current Pain and Headache Reports. 2006;10:34–38. doi: 10.1007/s11916-006-0007-1.
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: A descriptive study, 2002-2005. BMC Fam Pract. 2008;9:26. doi: 10.1186/1471-2296-9-26.
    1. Baron R, Wasner G. Prevention and treatment of postherpetic neuralgia. Lancet. 2006;367:186–188. doi: 10.1016/S0140-6736(06)68010-0.
    1. Dworkin RH, O'Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, Kalso EA, Loeser JD, Miaskowski C, Nurmikko TJ, Portenoy RK, Rice AS, Stacey BR, Treede RD, Turk DC, Wallace MS. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–251. doi: 10.1016/j.pain.2007.08.033.
    1. Jackson KC. Pharmacotherapy for neuropathic pain. Pain Pract. 2006;6:27–33. doi: 10.1111/j.1533-2500.2006.00055.x.
    1. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400. doi: 10.1016/S0304-3959(99)00154-2.
    1. Petersen KL, Fields HL, Brennum J, Sandroni P, Rowbotham MC. Capsaicin evoked pain and allodynia in post-herpetic neuralgia. Pain. 2000;88:125–133. doi: 10.1016/S0304-3959(00)00311-0.
    1. Bley KR. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin Investig Drugs. 2004;13:1445–1456. doi: 10.1517/13543784.13.11.1445.
    1. Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs. 2009;10:702–10.
    1. Bernstein JE, Korman NJ, Bickers DR, Dahl MV, Millikan LE. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol. 1989;21(2 Pt 1):265–270. doi: 10.1016/S0190-9622(89)70171-7.
    1. Peikert A, Hentrich M, Ochs G. Topical 0.025% capsaicin in chronic post-herpetic neuralgia: efficacy, predictors of response and long-term course. J Neurol. 1991;238:452–456. doi: 10.1007/BF00314653.
    1. Backonja MM, Malan TP, Vanhove GF, Tobias JK. the C102/106 Study Group NGX-4010. A High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia: A Randomized, Double-Blind, Controlled Study with an Open-Label Extension. Pain Medicine. 2010;11:600–8. doi: 10.1111/j.1526-4637.2009.00793.x.
    1. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P Jr, Rauck R, Tobias J. NGX-4010 C116 Study Group. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–1112. doi: 10.1016/S1474-4422(08)70228-X.
    1. Irving GA, Backonja M, Dunteman E, Vanhove GF, Lu S-P, Tobias JK. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Medicine. 2010. in press .
    1. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158. doi: 10.1016/S0304-3959(01)00349-9.
    1. Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, Reisberg B, Schmitt FA. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis Assoc Disord. 2006;20(4 Suppl 3):S124–S138. doi: 10.1097/01.wad.0000213878.47924.44.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129–138.
    1. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–197. doi: 10.1016/0304-3959(87)91074-8.
    1. Guidance for industry: skin irritation and sensitization testing of generic transdermal drug products.
    1. Kost RG, Straus SE. Postherpetic neuralgia - pathogenesis, treatment, and prevention. N Engl J Med. 1996;335:32–42. doi: 10.1056/NEJM199607043350107.
    1. Lauria G, Morbin M, Lombardi R, Capobianco R, Camozzi F, Pareyson D, Manconi M, Geppetti P. Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and in painful neuropathies. J Peripher Nerv Syst. 2006;11:262–267. doi: 10.1111/j.1529-8027.2006.0097.x.
    1. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 Agonist) Therapy for Pain Relief: Farewell or Revival? Clin J Pain. 2008;24:142–154. doi: 10.1097/AJP.0b013e318158ed9e.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren